Immunocore’s Phase III IMCgp100-202 trial of tebentafusp compared to investigator’s choice for metastatic uveal melanoma (mUM) met the pre-defined boundaries for statistical significance of the primary endpoint of overall survival in its first pre-planned interim analysis.
Novartis’ Beovu matched Regeneron’s Eylea in vision clarity scores for a blindness-causing eye disease, the Swiss drugmaker said, after early safety stumbles for the medicine in another condition caused disappointing early sales.
Johnson & Johnson Vision announced the launch of Prioritize Your Eyes, a worldwide effort to raise awareness about the connection of eye health to overall health.
Ireland’s Horizon Therapeutics became the first to win regulatory approval in the United States for the treatment of Thyroid Eye Disease (TED), a progressive autoimmune disorder that can threaten the vision of those afflicted.
The Dermatologic and Ophthalmic Drugs Advisory Committee of the U.S. Food and Drug Administration voted unanimously that the potential benefits of Horizon Therapeutics plc’s fully human monoclonal antibody teprotumumab outweighed the potential risks for the treatment of Thyroid Eye Disease (TED).
Horizon Pharma’s late-stage treatment teprotumumab for active thyroid eye disease continues to demonstrate greater efficacy. Two months after releasing positive Phase III data, the company shared additional secondary endpoint data that shows higher levels of patient benefit.
Horizon Pharma announced that new data from the Phase 3 confirmatory study evaluating teprotumumab for treating active thyroid eye disease were presented as part of a late-breaking oral presentation at the 2019 AACE Scientific and Clinical Congress.